---
schema_version: "secwatch.filing_event.v1"
accession: "0001279569-25-000181"
form_type: "8-K"
ticker: "CWBHF"
cik: "0001750155"
company_name: "Charlotte's Web Holdings, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:02:45.998470+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Charlotte's Web minority-interest DeFloria gets FDA clearance for Phase 2 autism trial

## Summary
- FDA cleared DeFloria's IND to proceed with Phase 2 trial of AJA001 Oral Solution for autism spectrum disorder symptoms.
- AJA001 uses Charlotte's Web proprietary full-spectrum CBD hemp extract from patented cultivars.
- Phase 2 will assess safety/tolerability/efficacy in adolescents and adults with ASD.
- DeFloria is a collaboration between Charlotte's Web (minority stake) and Ajna BioSciences PBC.
- CEO cites milestone in moving hemp genetics from consumer wellness to regulated medical sector.

## SEC filing metadata
- accession: 0001279569-25-000181
- form_type: 8-K
- ticker: CWBHF
- cik: 0001750155
- company_name: Charlotte's Web Holdings, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750155/000127956925000181/0001279569-25-000181-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750155/000127956925000181/charlotte8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001279569-25-000181
- JSON: https://secwatch.observer/filing/0001279569-25-000181.json
- Plain text: https://secwatch.observer/filing/0001279569-25-000181.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.